All News

Lungs breathing

ILD in RA and PsA

Aurelie Najm, MD, PhD

Interstitial lung disease (ILD) is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis.

Read Article
Convention1.jpg

EULAR 2023: Featured Industry Presentations

Jack Cush, MD

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR

Read Article
cush.tkr_.jpg

Colchicine and the Risk of Knee and Hip Replacement

Jack Cush, MD

Treatment of osteoarthritis is a major unmet need, as there are few therapies effective at pain control and no options for disease modification; yet a new trial in Annals of Internal Medicine suggest that chronic low dose colchicine may alter disease progression and lower the risk of of total knee and total hip replacements.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Belimumab in Lupus Nephritis

Jack Cush, MD

Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.

Read Article
brain,pain,perception,cns

Orbitofrontal Cortex Implants to Assess Chronic Pain

Jack Cush, MD

Nature Neuroscience reports a novel approach to assessing chronic neuropathic pain - intracranial electrodes in the anterior cingulate cortex and orbitofrontal cortex (OFC) to map chronic pain signaling. 

Read Article
RheumNow Podcast square

3-4-5 Rule (5.26.2023)

Jack Cush, MD

Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.

Read Article
lupus_0.jpg

Lupus Landmark Study to Accelerate Personalized Lupus Treatments

EurekAlert!

The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics today announced the launch of the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus.

Read Article
DXA1.jpg (keep)

FRAX Tool is Suboptimal in Predicting Osteoporosis Fracture Risk in Younger Post-menopausal Women

EurekAlert!

The commonly used Fracture Risk Assessment Tool (FRAX), which includes self-identified race and ethnicity information, and the Osteoporosis Self-Assessment Tool (OST), which does not, had suboptimal performance in determining major osteoporotic fracture risk across racial/ethnic categories in you

Read Article
ANCA, vasculitis, test

International Consensus on ANCA-Associated Vasculitis with Glomerulonephritis

Jack Cush, MD

Nephrology Dialysis Transplantation has published an overview of the management of anti-neutrophil cytoplasmic antibody associated vasculitis with glomerulonephritis based on several international guidelines, including those frorm the ACR 2021, EULAR 2022 and KDIGO 2021 (Kidney Disease: Improving

Read Article
EULAR PtoC management of targeted therapies in pts w/ IA & Hx cancer 1) If remission, initiate targeted therapy w/out delay 2) Prefer anti-cytokine bDMARDs if Hx solid cancer 3) B cell depleting therapy if Hx lymphoma 4) Use JAK inhibitors and abatacept with caution 🛑 https://t.co/cKhQVZwGh1
Aurelie Najm AurelieRheumo ( View Tweet)
Provan et al. large scandinavian registry study: 🫁ILD risk in RA & PsA initiating b/tsDMARDs HR ILD RA=10 HR ILD PsA=5 No increase risk w/ MTX and b/tsDMARDs but RA HR ILD 1.7 RTX vs. ETA: confounding by indication? https://t.co/CF1ysNkQxU OP0006 #EULAR23 @Rheumnow https://t.co/DgDE1uFeUs

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
New benefit/risk outlook 👀 on ORAL surveillance 2 subgrps: 🟢RA w/ no previous Hx of atherosclerotic CV dis = TOFA at least as good as TNFi AND risk of MACE is comparable 🛑RA w/ HxASCVD = efficacy TOFA = TNFi AND > risk of MACE https://t.co/VOxNQSoyY4 OP0043 #EULAR23 @Rheumnow https://t.co/m98eSMG03U

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Biosimilar vs originator: as switches loom in the US, once again it’s really hard to say we see any differences in drug survival for our RA patients These data from forced switching in BC, Canada are just like the others - biosimilars are business as usual. POS0567 #EULAR2023 https://t.co/Ebl1hTM4qE
David Liew drdavidliew ( View Tweet)
Ongoing work to #classify #inflammatory #arthritis in Pts using #check #point #inhibitors. A 1st step to study the etiology of immune changes from these life prolonging medications #EULAR2023 @RheumNow https://t.co/Bv1q8IphqF

Links:

Janet Pope Janetbirdope ( View Tweet)

Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/8BMTmJqhPq https://t.co/BOMsk38KB2

Links:

Dr. John Cush RheumNow ( View Tweet)
PREVENT study looked at Xray progression in 438 nr-axSpA pts given PBO or secukinumab. At baseline there was little SI damage & at 2 yrs no SI progression (− 0.04 mSASSS) or spinal inflammation in both groups. https://t.co/3EgnK2rWgb https://t.co/z5umUhpViF

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
Ph 3 study 800 ICU pts w/ severe community acq pneumonia shows those on IV hydrocortisone had lower mortality at day 28 (6.2% vs 11.9%; P=0.006), less intubation (18% vs 29.5%), less vasopressors (15% v 25%) vs PBO; no Diff w/ infx rates or GI bleed https://t.co/BjIM8UJXZS https://t.co/389CZovrZm

Links:

Dr. John Cush RheumNow ( View Tweet)
Allergic Drug - Induced Arthritis Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies. https://t.co/AmpWG2Siii https://t.co/PwEgVHfDu8

Links:

Dr. John Cush RheumNow ( View Tweet)
MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab. https://t.co/xGPSA2oRis https://t.co/y7M42DlM7d

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×